[{"id":"295b0561-593e-4af2-bcb7-0b0537450f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896737","created_at":"2021-01-18T19:11:30.460Z","updated_at":"2024-07-02T16:35:37.895Z","phase":"Phase 2","brief_title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","source_id_and_acronym":"NCT03896737","lead_sponsor":"European Myeloma Network","biomarkers":" IGH","pipe":" | ","alterations":" IGH translocation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-07"}]